Preliminary application of 125 I –nivolumab to detect PD-1 expression in colon cancer via SPECT

AbstractThe precise detection of PD-1/PD-L1 biomarkers helps to predict the prognosis of corresponding immunotherapy.125I-labeled nivolumab targeting activated immune cells infiltrating the tumorous tissues was developed to evaluate the expression of PD-1 immune checkpoints. SPECT images indicated that125I –nivolumab preferentially targeted to tumor-surrounded immune cells. This radiotracer can dynamically and quantitatively characterize the in vivo expression of immune checkpoints for colorectal cancer, thereby potentially enabling the early screening of patients, monitoring the efficacy of treatme nt, and assessing potential immunotoxicity.
Source: Journal of Radioanalytical and Nuclear Chemistry - Category: Nuclear Medicine Source Type: research